Breaking News Instant updates and real-time market news.

VRTX

Vertex

$172.56

-0.63 (-0.36%)

, NBIX

Neurocrine

$94.32

-0.91 (-0.96%)

04:55
09/13/19
09/13
04:55
09/13/19
04:55

SVB Leerink to hold a summit

West Coast Biopharma Summit will be held in San Francisco on September 12-13.

VRTX

Vertex

$172.56

-0.63 (-0.36%)

NBIX

Neurocrine

$94.32

-0.91 (-0.96%)

KURA

Kura Oncology

$16.13

-0.245 (-1.50%)

AMGN

Amgen

$193.97

-1.76 (-0.90%)

SGEN

Seattle Genetics

$70.92

0.07 (0.10%)

TPTX

Turning Point Therapeutics

$44.66

-0.355 (-0.79%)

XNCR

Xencor

$35.51

-0.77 (-2.12%)

  • 13

    Sep

  • 16

    Sep

  • 19

    Sep

  • 19

    Sep

  • 20

    Sep

  • 27

    Sep

  • 19

    Mar

VRTX Vertex
$172.56

-0.63 (-0.36%)

09/03/19
GSCO
09/03/19
UPGRADE
Target $254
GSCO
Conviction Buy
Vertex upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter added Vertex Pharmaceuticals to his firm's Americas Conviction List while raising his price target for the shares to $254 from $226 and keeping a Buy rating on the name. Vertex is in the midst of a multi-year period of "rapid" margin expansion and earnings outperformance driven by growth of the legacy cystic fibrosis franchise and likely launch of VX-445 triple combination, which has a March 19 FDA action date, Richter tells investors in a research note. Further, the analyst believes investor attention should now shift to the company's emerging pipeline, where he sees a "significant opportunity" in the Phase 2-ready alpha-1 antitrypsin deficiency disorder program.
08/28/19
PIPR
08/28/19
NO CHANGE
Target $230
PIPR
Overweight
Vertex drug not cited as cause of 30 deaths in FDA database, says Piper Jaffray
The FDA Adverse Events Reporting System Public Dashboard citing 30 deaths with Symdeko caused volatility today in shares of Vertex Pharmaceuticals, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. After accessing the website, the analyst says none of the 30 deaths specifically indicate Symdeko, "but rather appear to be due to underlying cystic fibrosis disease." As such, the FAERS report does not signify a unique problem with Symdeko or Vertex's TripleRx combination, which is under review at the FDA, contends Tenthoff. The "timing of this short rumor to be suspicious during a quiet, end of summer week," he adds. The analyst continues to forecast Vertex's total cystic fibrosis sales at $3.7B this year, growing to $5B in 2020 with the TripleRx launch. He reiterates an Overweight rating on the stock with a $230 price target. Vertex in late morning trading is up 1%, or $1.84, to $180.09.
08/28/19
ARGS
08/28/19
NO CHANGE
Target $200
ARGS
Buy
Vertex offers attractive entry point, says Argus
Argus analyst Jasper Hellweg keeps his Buy rating and $200 price target on Vertex but notes that its recent stock price retreat has taken valuation below historical averages and offers a "favorable entry point". The analyst is positive on the company's current product line-up and deep pipeline focused on cystic fibrosis drugs, with an eye on the March 2020 FDA action date for its next-generation triple-combination CF therapy regimen.
08/28/19
PIPR
08/28/19
NO CHANGE
PIPR
Symdeko deaths in FDA database likely due to disease, says Piper Jaffray
NBIX Neurocrine
$94.32

-0.91 (-0.96%)

08/28/19
GSCO
08/28/19
NO CHANGE
Target $110
GSCO
Buy
Slower Orilissa ramp has minimal impact on Neurocrine, says Goldman Sachs
To reflect the slower than expected ramp in sales of Orilissa in endometriosis, Goldman Sachs analyst Paul Choi lowered his Neurocrine Biosciences (NBIX) forecasts of Orilissa royalties. He projects similar 40% market share by 2026 for both Myovant Sciences' (MYOV) relugolix and Orilissa within endometriosis and uterine fibroid patients treated with a GnRH receptor antagonists. However, in the near-term, since Orilissa royalties are a small fraction of Neurocrine's revenue, these changes have little impact on the company's top- and bottom- lines, says Choi. As such, the analyst keeps a Buy rating on Neurocrine Biosciences with a $110 price target.
07/30/19
FBCO
07/30/19
NO CHANGE
Target $110
FBCO
Outperform
Neurocrine price target raised to $110 from $95 at Credit Suisse
Credit Suisse analyst Evan Seigerman raised his price target for Neurocrine to $110 from $95 and raised Ingrezza sales to $200M in Q3 following the "solid" quarterly beat. The analyst believes that Ingrezza has much more room to grow, and that the company's expanded promotional efforts are likely to drive continued penetration into the addressable TD market which he estimates to be over 500k patients in the U.S. Seigerman reiterates an Outperform rating on the shares.
08/07/19
RBCM
08/07/19
INITIATION
Target $118
RBCM
Outperform
Neurocrine initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams initiated Neurocrine with an Outperform rating and a price target of $118, saying the company's "high-growth, low-risk" profile should "continue to stand out." The analyst is positive on Neurocrine's strong near-term Ingrezza growth based on his market analysis, current trends, and physician feedback. Abrahams also believes the company has the potential for pipeline candidates to drive incremental longer-term revenue growth and sees that opportunity as "underappreciated" in the market.
08/07/19
08/07/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Bilibili (BILI) initiated with a Buy at Goldman Sachs. 2. Waste Connections (WCN) was initiated with an Overweight at JPMorgan, while Waste Management (WM) and Republic Services (RSG) were initiated with a Neutral. 3. Neurocrine (NBIX) initiated with an Outperform at RBC Capital. 4. Brookfield Property (BPY) initiated with an Outperformer at CIBC. 5. Dropbox (DBX) initiated with an Underperform at Bernstein. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
KURA Kura Oncology
$16.13

-0.245 (-1.50%)

09/05/19
JMPS
09/05/19
INITIATION
Target $22
JMPS
Outperform
Kura Oncology resumed with an Outperform at JMP Securities
JMP Securities analyst Reni Benjamin resumed coverage of Kura Oncology with an Outperform rating and a price target of $22, adding that the bull case price target on the stock is $35. The analyst estimates that the company's Tipifarnib, its lead asset that is currently tested in multiple biomarker-defined cancer indications, could reach risk-adjusted peak sales of $802M in 2027 while contributing to its projected earnings of $3.34 per share. Based on the positive results of Tipifarnib in multiple biomarker-defined population and a "catalyst-rich" backdrop in 2019-2020, Benjamin contends that Kura Oncology shares are "attractively priced".
06/14/19
HCWC
06/14/19
NO CHANGE
Target $31
HCWC
Buy
Kura reported 'crucial' biomarker set of data, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating and $31 price target on Kura Oncology after the company announced positive follow-up data from the ongoing Phase 2 clinical trial addressing the anti-tumor role of tipifarnib in PTCL patients and met the primary endpoint. In a research note to investors, the analyst says Kura reported a crucial biomarker set of data, the enrichment of high rate of mutation/variation of the killer cell immunoglobulin-like receptors, including KIR3DL2 in AITL patients and its role in tipifarnib outcome. Kura's targeted approaches could generate fast and meaningful information on crucial tumor indications and patient cohorts where tipifarnib may see more robust clinical outcomes, increasing his confidence on tipifarnib's likelihood of success, the analyst contends.
07/18/19
DBAB
07/18/19
INITIATION
Target $28
DBAB
Buy
Kura Oncology initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Konstantinos Aprilakis started Kura Oncology with a Buy rating and $28 price target. The analyst initiated coverage on eight smid-cap Biotechnology stocks in the oncology space.
06/17/19
WEDB
06/17/19
NO CHANGE
Target $30
WEDB
Outperform
Kura Oncology price target raised to $30 from $23 at Wedbush
Wedbush analyst Robert Driscoll raised his price target for Kura Oncology to $30 from $23 after the company announced positive data from an ongoing Phase 2 study evaluating tipifarnib in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma patients carrying a CXCL12 3' UTR SNP. Overall, the analyst views the "impressive" data set as highly supportive of a registrational pathway in AITL/PTCL CXCL12+ patients, and further validating of the broadening clinical development of tipifarnib into additional indications to potentially include pancreatic, DLBCL, and AML. Driscoll reiterates an Outperform rating on the shares.
AMGN Amgen
$193.97

-1.76 (-0.90%)

09/09/19
CANT
09/09/19
NO CHANGE
Target $81
CANT
Neutral
Cantor warrants caution on Mirati after Amgen data, sees 7%-11% selloff
Cantor Fitzgerald analyst Varun Kumar warrants caution on shares of Mirati Therapeutics (MRTX) ahead of its MRTX849 data following Amgen's (AMGN) update from its KRAS G12C program, AMG 510. Updated response rates data "are not a 'slam dunk' as may have been broadly expected, and further follow-up is needed for a more-matured verdict," Kumar tells investors in a research note. Further, durability will likely be the talking point in the near term, as KRASi G12C market size needs to be carefully assessed versus what's currently reflected by market estimates, adds the analyst. He thinks Mirati shares could trade down 7%-11% given some caution on the response rate trend as the cohort size gets larger and due to an increasing focus on response durability, which he thinks may change the U.S. peak sales estimates for KRAS G12C non-small-cell lung carcinoma market to $1.8B-$3.6B. Kumar lowered his price target for Mirati Therapeutics to $81 from $85 and reiterates a Neutral rating on the name. The stock in premarket trading is down 4% to $87.27. Jefferies this morning upgraded the shares to Buy following Amgen's data.
09/09/19
JEFF
09/09/19
NO CHANGE
Target $235
JEFF
Buy
Jefferies sees blockbuster drug for Amgen, says buy shares on selloff
Amgen's new lung data shows a 54% overall response rate at the high dose, which is "very strong," yet at the lower end of Street expectations, Jefferies analyst Michael Yee tells investors in a research note. The analyst says his thesis remains "very positive" and that Amgen should be bought on any weakness today following the data. AMGN-510 "looks like a blockbuster drug," says Yee, who keeps a Buy rating on Amgen with a $235 price target.
09/09/19
JEFF
09/09/19
UPGRADE
Target $105
JEFF
Buy
Mirati Therapeutics upgraded to Buy from Hold at Jefferies
Jefferies analyst Maury Raycroft upgraded Mirati Therapeutics (MRTX) to Buy from Hold and raised his price target for the shares to $105 from $89. The analyst believes the bar for initial Mirati data has been lowered after Amgen (AMGN) announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. Pharmacokinetic variability could become a liability for Amgen, which opens the window wider for Mirati's MRTX849 to be "best-in-class," Raycroft tells investors in a research note.
09/12/19
LEER
09/12/19
NO CHANGE
LEER
Market Perform
Amgen halt of enrollment for cardiac toxicity 'unexpected,' says SVB Leerink
SVB Leerink analyst Geoffrey Porges said Amgen's disclosure earlier this morning that Phase 1 enrollment for AMG397 and AMG176 studies has been halted due to cardiac toxicity safety signals was unexpected. While not specific to AMG176 or AMG397, there is some pre-clinical evidence that MCL-1 inhibition can induce rapid and fatal heart failure, the analyst stated. Porges said he has not yet included revenue for AMG176 in his model, but having this product in the portfolio "added to the attractiveness of Amgen's stock," stated the analyst, who keeps a Market Perform rating on Amgen shares.
SGEN Seattle Genetics
$70.92

0.07 (0.10%)

07/18/19
DBAB
07/18/19
INITIATION
Target $79
DBAB
Hold
Seattle Genetics initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Konstantinos Aprilakis started Seattle Genetics with a Hold rating and $79 price target. The analyst initiated coverage on eight smid-cap Biotechnology stocks in the oncology space.
08/26/19
BTIG
08/26/19
INITIATION
BTIG
Neutral
Seattle Genetics initiated with a Neutral at BTIG
BTIG analyst Thomas Shrader initiated Seattle Genetics with a Neutral rating. The analyst is positive on the company's antibody drug conjugate, or ADC, leadership and its efforts to broaden that label in Hodgkin lymphoma, but warns that its next growth leg for the new generation of ADCs will involve in diseases that are "much tougher" to treat and come against greater competition. Shrader also believes that much of the good news for Seattle Genetics has been priced into the stock.
09/12/19
OPCO
09/12/19
UPGRADE
OPCO
Outperform
Seattle Genetics upgraded to Outperform from Perform at Oppenheimer
09/12/19
09/12/19
UPGRADE
Target $82

Outperform
Seattle Genetics upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Silvan Tuerkcan upgraded Seattle Genetics to Outperform from Perform based on his review of pipeline assets Enfortumab Vedotin and tucatinib that focus on less competitive later lines of treatment with strong data. The analyst also notes that recent weakness in the shares presents an attractive entry point ahead of several pipeline catalysts. Tuerkcan raised his price target on the stock to $82 from $77.
TPTX Turning Point Therapeutics
$44.66

-0.355 (-0.79%)

09/09/19
WEDB
09/09/19
INITIATION
Target $63
WEDB
Outperform
Turning Point Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated Turning Point Therapeutics with an Outperform rating and $63 price target.
09/10/19
09/10/19
INITIATION
Target $63

Outperform
Wedbush bullish on Turning Point Therapeutics, initiates with an Outperform
As previously reported, Wedbush analyst David Nierengarten started coverage of Turning Point Therapeutics with an Outperform rating and $63 price target. The analyst believes shares are "undervalued," as the company's portfolio of selective TKIs for cancers driven by alterations in ROS1, NTRK, ALK, MET and RET offers blockbuster and best-in-class potential over currently-available or emerging alternatives.
09/04/19
WELS
09/04/19
NO CHANGE
Target $62
WELS
Outperform
Turning Point Therapeutics price target raised to $62 from $53 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Turning Point Therapeutics to $62 from $53 following updated interim phase 1/2 TRIDENT-1 data for repotrectinib in ROS1+ NSCLC and TRK+ solid tumors. The analyst reiterates an Outperform rating on the shares.
09/10/19
09/10/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DuPont (DD) initiated with a Buy at Jefferies. 2. Turning Point Therapeutics (TPTX) initiated with an Outperform at Wedbush. 3. Aurinia Pharmaceuticals (AUPH) initiated with an Outperform at Oppenheimer. 4. Banco de Chile (BCH) initiated with a Neutral at Goldman Sachs. 5. McEwen Mining (MUX) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
XNCR Xencor
$35.51

-0.77 (-2.12%)

08/08/19
CANT
08/08/19
NO CHANGE
Target $40
CANT
Overweight
Xencor post earnings selloff yesterday overdone, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young views the post-earnings selloff yesterday in shares of Xencor as overdone. While the company shifted timelines for SSTR2xCD3 and PD-1xCTLA-4 assets from end of 2019 to the first half of 2020, the selloff yesterday was likely an overreaction, Young tells investors in a research note. She thinks Xencor's platform value remains the same and views the company as very well capitalized with $625M in cash. The analyst reiterates an Overweight rating on the shares with a $40 price target.
08/07/19
GUGG
08/07/19
DOWNGRADE
GUGG
Neutral
Xencor downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Michael Schmidt downgraded Xencor to Neutral from Buy saying he's looking for a more attractive entry point.
08/08/19
ADAM
08/08/19
NO CHANGE
Target $52
ADAM
Buy
Xencor price target raised to $52 from $45 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Xencor to $52 from $45 citing its commercial product Xtend which is already generating sales, multiple partnered programs, and wholly owned programs progressing through the clinic. Lee reiterated her Buy rating on Xencor shares.
08/07/19
WEDB
08/07/19
NO CHANGE
Target $54
WEDB
Outperform
Xencor price target raised to $54 from $43 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Xencor (XNCR) to $54 from $43 as he believes it remains a de-risked platform name, no near-term cash needs, and with support for its valuation from Alexion (ALXN) Ultomiris royalties, and a potentially more significant royalty stream from tafasitamab with multiple early-stage pipeline candidates to provide future upside. The analyst reiterates an Outperform rating on Xencor's shares.

TODAY'S FREE FLY STORIES

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:08
10/22/19
10/22
21:08
10/22/19
21:08
Earnings
Breaking Earnings news story on Euronet »

Euronet sees Q4 EPS $1.61…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:07
10/22/19
10/22
21:07
10/22/19
21:07
Hot Stocks
Euronet says revenue growth would have been stronger if not for strong USD »

CEO Michael Brown says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:06
10/22/19
10/22
21:06
10/22/19
21:06
Hot Stocks
Euronet reports Q3 adjusted EBITDA $227.3M vs. $181.4M last year »

Reports Q3 transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

EEFT

Euronet

$143.81

-2.84 (-1.94%)

21:04
10/22/19
10/22
21:04
10/22/19
21:04
Earnings
Euronet reports Q3 adjusted EPS $2.84, consensus $2.80 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

  • 14

    Nov

FFWM

First Foundation

$15.50

0.16 (1.04%)

21:03
10/22/19
10/22
21:03
10/22/19
21:03
Earnings
First Foundation reports Q3 EPS 39c, consensus 36c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

KMB

Kimberly-Clark

$129.57

-9.74 (-6.99%)

20:36
10/22/19
10/22
20:36
10/22/19
20:36
Upgrade
Kimberly-Clark rating change at Deutsche Bank »

Kimberly-Clark upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BA

Boeing

$337.45

6.33 (1.91%)

, TMO

Thermo Fisher

$280.89

-2.56 (-0.90%)

20:25
10/22/19
10/22
20:25
10/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BA

Boeing

$337.45

6.33 (1.91%)

TMO

Thermo Fisher

$280.89

-2.56 (-0.90%)

LLY

Eli Lilly

$110.00

2.06 (1.91%)

CAT

Caterpillar

$133.69

1.47 (1.11%)

ANTM

Anthem

$260.28

7.12 (2.81%)

BX

Blackstone

$49.08

-0.025 (-0.05%)

BSX

Boston Scientific

$38.21

-0.45 (-1.16%)

GD

General Dynamics

$179.92

4.49 (2.56%)

NSC

Norfolk Southern

$188.85

2.68 (1.44%)

HLT

Hilton

$90.81

-1.57 (-1.70%)

FCX

Freeport McMoRan

$9.92

0.1 (1.02%)

IVZ

Invesco

$16.03

-0.115 (-0.71%)

OC

Owens Corning

$63.41

-0.055 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 02

    Dec

  • 07

    Dec

ACRS

Aclaris Therapeutics

$1.62

0.215 (15.36%)

20:13
10/22/19
10/22
20:13
10/22/19
20:13
Upgrade
Aclaris Therapeutics rating change at SVB Leerink »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

AMGN

Amgen

$204.84

1.93 (0.95%)

19:39
10/22/19
10/22
19:39
10/22/19
19:39
Hot Stocks
Amgen CFO David Meline to retire »

Amgen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 07

    Dec

TRV

Travelers

$130.22

-11.55 (-8.15%)

19:31
10/22/19
10/22
19:31
10/22/19
19:31
Upgrade
Travelers rating change at Deutsche Bank »

Travelers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

GOOG

Alphabet

$1,242.78

-3.45 (-0.28%)

, GOOGL

Alphabet Class A

$1,241.08

-3.15 (-0.25%)

19:09
10/22/19
10/22
19:09
10/22/19
19:09
Periodicals
State AGs plan Google antitrust meeting next month, Reuters says »

U.S. state attorneys…

GOOG

Alphabet

$1,242.78

-3.45 (-0.28%)

GOOGL

Alphabet Class A

$1,241.08

-3.15 (-0.25%)

FB

Facebook

$182.27

-7.55 (-3.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

CISN

Cision

$10.08

1.63 (19.29%)

19:03
10/22/19
10/22
19:03
10/22/19
19:03
Downgrade
Cision rating change at BMO Capital »

Cision downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MANH

Manhattan Associates

$74.47

-2.02 (-2.64%)

, TER

Teradyne

$59.24

-0.83 (-1.38%)

18:55
10/22/19
10/22
18:55
10/22/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MANH

Manhattan Associates

$74.47

-2.02 (-2.64%)

TER

Teradyne

$59.24

-0.83 (-1.38%)

CSL

Carlisle

$144.97

-0.27 (-0.19%)

USNA

Usana

$72.62

2.92 (4.19%)

NAVI

Navient

$12.16

0.19 (1.59%)

DFS

Discover

$81.30

0.85 (1.06%)

HNGR

Hanger

$20.50

0.39 (1.94%)

MRNA

Moderna

$15.90

0.42 (2.71%)

REZI

Resideo

$15.17

0.03 (0.20%)

IRBT

iRobot

$53.88

-1.82 (-3.27%)

TXN

Texas Instruments

$128.61

-2.32 (-1.77%)

INTC

Intel

$52.00

-0.12 (-0.23%)

ADI

Analog Devices

$110.91

-0.18 (-0.16%)

AVGO

Broadcom

$287.54

-2.03 (-0.70%)

NVDA

Nvidia

$195.52

-0.64 (-0.33%)

QCOM

Qualcomm

$78.46

-0.5 (-0.63%)

AMD

AMD

$31.51

-0.54 (-1.68%)

HA

Hawaiian Holdings

$30.14

0.67 (2.27%)

SIX

Six Flags

$51.22

-0.62 (-1.20%)

WHR

Whirlpool

$160.72

0.18 (0.11%)

BYD

Boyd Gaming

$26.17

0.24 (0.93%)

CMG

Chipotle

$831.69

-20.195 (-2.37%)

SNAP

Snap

$14.00

-0.58 (-3.98%)

SKX

Skechers

$38.03

0.55 (1.47%)

SLNO

Soleno Therapeutics

$1.50

0.03 (2.04%)

NOW

ServiceNow

$228.26

-12.315 (-5.12%)

NKE

Nike

$95.61

-0.61 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 31

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 09

    Dec

  • 12

    Dec

  • 23

    Oct

IIPR

Innovative Industrial Properties

$72.50

-1.2 (-1.63%)

18:53
10/22/19
10/22
18:53
10/22/19
18:53
Hot Stocks
Innovative Industrial Properties investing $46.6M in two IL properties »

Innovative Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CISN

Cision

$10.08

1.63 (19.29%)

18:51
10/22/19
10/22
18:51
10/22/19
18:51
Downgrade
Cision rating change at BMO Capital »

Cision downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

LOGI

Logitech

$39.97

-0.75 (-1.84%)

18:42
10/22/19
10/22
18:42
10/22/19
18:42
Hot Stocks
Logitech CEO: We had a solid quarter despite macroeconomic noise »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Nov

  • 05

    Nov

HAS

Hasbro

$100.00

-20.11 (-16.74%)

18:23
10/22/19
10/22
18:23
10/22/19
18:23
Hot Stocks
Hasbro CEO: We believe we can grow in Q4 »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

SPY

SPDR S&P 500 ETF Trust

$299.01

-1.04 (-0.35%)

, SPX

S&P 500

$0.00

(0.00%)

18:22
10/22/19
10/22
18:22
10/22/19
18:22
General news
Trump tweets 'good news happening' on Turkey, Syria, Middle East »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$299.01

-1.04 (-0.35%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$69.11

0.37 (0.54%)

18:20
10/22/19
10/22
18:20
10/22/19
18:20
Periodicals
NY AG's office says Exxon should pay up to $1.6B in climate trial, NYP says »

Kevin Wallace, a lawyer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

XOM

Exxon Mobil

$69.11

0.37 (0.54%)

17:58
10/22/19
10/22
17:58
10/22/19
17:58
Periodicals
Exxon lawyer slams NY climate suit as trial opens, Bloomberg says »

Exxon Mobil attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

TER

Teradyne

$59.24

-0.83 (-1.38%)

17:57
10/22/19
10/22
17:57
10/22/19
17:57
Hot Stocks
Teradyne jumps 6% after quarterly results, guidance based on 5G demand »

Shares of semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

TER

Teradyne

$59.24

-0.83 (-1.38%)

17:53
10/22/19
10/22
17:53
10/22/19
17:53
Earnings
Teradyne sees Q4 EPS 73c-84c, consensus 61c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

LEVI

Levi Strauss

$17.59

0.58 (3.41%)

17:52
10/22/19
10/22
17:52
10/22/19
17:52
Hot Stocks
Levi Strauss EVP Love sells 204K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$46.15

0.48 (1.05%)

, WFC

Wells Fargo

$50.63

0.18 (0.36%)

17:51
10/22/19
10/22
17:51
10/22/19
17:51
Periodicals
BNY Mellon vice chairman leaves lender, WSJ says »

Bill Daley, former White…

BK

BNY Mellon

$46.15

0.48 (1.05%)

WFC

Wells Fargo

$50.63

0.18 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 29

    Oct

  • 12

    Nov

  • 14

    Jan

FMBI

First Midwest

$20.13

0.11 (0.55%)

17:42
10/22/19
10/22
17:42
10/22/19
17:42
Earnings
First Midwest reports Q3 adjusted EPS 52c, consensus 49c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.